依托尼秦
外观
![]() | |
![]() | |
临床资料 | |
---|---|
ATC码 |
|
法律规范状态 | |
法律规范 |
|
识别信息 | |
| |
CAS号 | 911-65-9 ![]() |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.011.827 |
化学信息 | |
化学式 | C22H28N4O3 |
摩尔质量 | 396.49 g·mol−1 |
3D模型(JSmol) | |
| |
|
依托尼秦(别名EA-4941、CS-4640[2])是一种苯并咪唑阿片类化合物,最早于1957年被报道,[3]它在动物实验中的药效约为吗啡的1000至1500倍。[4]
它在中国于2013年11月被列入《麻醉药品品种目录(2013年版)》并受到管制。[5]
参考文献
[编辑]- ^ Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control]. Diário Oficial da União. 2023-03-31 (2023-04-04) [2023-08-16]. (原始内容存档于2023-08-03) (巴西葡萄牙语).
- ^ King JW, Cleveland JP, Lennox WJ. Williams JD, Reeves PJ , 编. Synthesis and Bioactivity of 2-(Alpha-Hydroxy-Para-Alkoxybenzyl) and 2-Alkoxy Arylamino Analogs of Etonitazene (CS - 4640). Proceedings of the U.S. Army Chemical Research, Development and Engineering Center Scientific Conference on Chemical Defense Research. Aberdeen Proving Ground, Maryland: Edgewood Research, Development and Engineering Center, Aberdeen Proving Ground, MD. November 1991.
- ^ US patent 2935514,Hoffmann K, Hunger A, Kebrle J, Rossi A,“Benzimidazoles”,发表于1957-09-19,发行于1960-05-03,指定于Ciba Pharmaceutical Products Inc., Summit, NJ.
- ^ Wikler A, Martin WR, Pescor FT, Eades CG. Factors Regulating Oral Consumption of an Opioid (Etonitazene) by Morphine-Addicted Rats. Psychopharmacologia. October 1963, 5 (1): 55–76. PMID 14082382. S2CID 38073529. doi:10.1007/BF00405575.
- ^ 食品药品监管总局 公安部 国家卫生计生委关于公布麻醉药品和精神药品品种目录的通知. 国家药品监督管理局. 2013-11-11 [2025-06-21].